Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status

For the treatment of gastroesophageal reflux disease, intragastric pH should be lower than 4.0 for no more than 4 hours a day (<16.7%). We aimed to develop optimal dosage regimens for rabeprazole to control nocturnal acidity in relation to cytochrome P450 (CYP) 2C19 genotypes.

• Publication year

  2004

• Venue

  Clinical pharmacology and therapy

• Publication date

  2004-10-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.clpt.2004.06.008PMID 15470328
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized trial of rifabutin‐based triple therapy and high‐dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin

  2006cited by this paper
• Pharmacogenomics of proton pump inhibitors.

  2004cited by this paper
• Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night‐time gastric acid suppression

  2004cited by this paper
• Therapeutic impact of CYP2C19 pharmacogenetics on proton pump inhibitor-based eradication therapy for Helicobacter pylori.

  2003cited by this paper
• CYP2C19 pharmacogenetics in the clinical use of proton‐pump inhibitors for gastro‐oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms

  2003cited by this paper
• High‐dose rabeprazole–amoxicillin versus rabeprazole–amoxicillin–metronidazole as second‐line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection

  2003cited by this paper
• High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin.

  2003cited by this paper
• A Prospective, Randomized Study of Quadruple Therapy and High‐Dose Dual Therapy for Treatment of Helicobacter Pylori Resistant to Both Metronidazole and Clarithromycin

  2003cited by this paper
• Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects

  2003cited by this paper
• Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night‐time in different CYP2C19 genotype groups

  2002cited by this paper
• Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers

  2002cited by this paper
• Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19

  2002cited by this paper
• Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes

  2001cited by this paper
• Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin.

  2001cited by this paper
• Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism

  2001cited by this paper
• Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin

  2001cited by this paper
• Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH

  2001cited by this paper
• Effect of high‐dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19

  2001cited by this paper
• Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis

  2001cited by this paper
• Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.

  2000cited by this paper
• Epidemiology of esophageal and supraesophageal reflux injuries.

  2000cited by this paper
• CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole

  2000cited by this paper
• Helicobacter pylori infection influences nocturnal gastric acid breakthrough

  2000cited by this paper
• Medical therapy. Management of the refractory patient.

  1999influential reference
• Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world.

  1999cited by this paper
• CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans

  1999cited by this paper
• Review article: cytochrome P450 and the metabolism of proton pump inhibitors — emphasis on rabeprazole

  1999cited by this paper
• Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects.

  1998cited by this paper
• Effect of Genetic Differences in Omeprazole Metabolism on Cure Rates for Helicobacter pylori Infection and Peptic Ulcer

  1998cited by this paper
• A placebo‐controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24‐h intragastric acidity and plasma gastrin concentrations in young healthy male subjects

  1998cited by this paper
• CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans.

  1998cited by this paper
• Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors

  1998cited by this paper
• Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily

  1998cited by this paper
• Pharmacokinetics, Metabolism and Interactions of Acid Pump Inhibitors

  1996cited by this paper
• CYP2C19 genotype and phenotype determined by omeprazole in a Korean population.

  1996cited by this paper
• Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C gamma P2C19m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects.

  1996cited by this paper
• Genotyping of S‐mephenytoin 4′‐hydroxylation in an extended Japanese population

  1996cited by this paper
• Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, CYP2C19m1 in exon 5 and CYP2C19m2 in exon 4, in Japanese subjects

  1996cited by this paper
• The role of proton pump inhibitors in the treatment of gastro‐oesophageal reflux disease

  1995influential reference
• Pharmacological Management of Gastro-Oesophageal Reflux Disease

  1995cited by this paper
• Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype.

  1995cited by this paper
• Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19.

  1995cited by this paper
• Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S‐mephenytoin 4′‐hydroxylation status

  1995cited by this paper
• Long-Term Treatment with Omeprazole for Refractory Reflux Esophagitis: Efficacy and Safety

  1994influential reference
• The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.

  1994cited by this paper
• Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese.

  1994cited by this paper
• Appropriate acid suppression for the management of gastro-oesophageal reflux disease.

  1992influential reference
• Open-access upper alimentary endoscopy.

  1989cited by this paper
• Open-access upper alimentary endoscopy.

  1989cited by this paper
• Symptomatic gastroesophageal reflux: Incidence and precipitating factors

  1976cited by this paper

• CYP2C19 genotype-guided dosing of proton pump inhibitors: progress in clinical trials and real-world use

  2026cites this paper
• First assessments of nutrient bioaccessibility with an INFOGEST semi-dynamic gastric digestion in vitro protocol adapted to model proton pump inhibitor use.

  2025cites this paper
• The efficacy and safety of high‐dose amoxicillin‐bismuth‐potassium competitive acid blocker therapy for Helicobacter pylori infection—A pilot study

  2025cites this paper
• Eradication Therapy for Helicobacter pylori Infection in Patients Receiving Hemodialysis: Review

  2024cites this paper
• Independent Risk Factors Predicting Eradication Failure of Hybrid Therapy for the First-Line Treatment of Helicobacter pylori Infection

  2023influential citation
• Hybrid, High-Dose Dual and Bismuth Quadruple Therapies for First-Line Treatment of Helicobacter pylori Infection in Taiwan: A Multicenter, Open-Label, Randomized Trial

  2023cites this paper
• Expectations for the Dual Therapy with Vonoprazan and Amoxicillin for the Eradication of H. pylori

  2023cites this paper
• Update on the second-line treatment of Helicobacter pylori infection: a narrative review

  2023cites this paper
• Exploring Differences in Pharmacometrics of Rabeprazole between Genders via Population Pharmacokinetic–Pharmacodynamic Modeling

  2023cites this paper
• The prospective multiple-centre randomized controlled clinical study of high-dose amoxicillin-proton pump inhibitor dual therapy for H. pylori infection in Sichuan areas

  2022cites this paper
• The efficacy of culture‐guided versus empirical therapy with high‐dose proton pump inhibitor as third‐line treatment of Helicobacter pylori infection: A real‐world clinical experience

  2022cites this paper
• Update on the first-line treatment of Helicobacter pylori infection in areas with high and low clarithromycin resistances

  2022cites this paper
• Efficacy, safety and cost-effectiveness of vonoprazan vs Proton Pump Inhibitors in reflux disorders and H. pylori eradication: A literature review

  2022cites this paper
• The CYP2C19 polymorphisms effects on H. pylori cure rate in proton pump inhibitor-based therapeutic regimens: An updated meta-analysis

  2021cites this paper
• The effect of PPIs Alone, PPIs plus cytoprotective agent, and H2RA plus cytoprotective agent on ulcer healing after endoscopic submucosal dissection: A prospective randomized controlled trial.

  2021cites this paper
• Influence of Cytochrome P450 2C19 Genotype on Helicobacter pylori Proton Pump Inhibitor-Amoxicillin-Clarithromycin Eradication Therapy: A Meta-Analysis

  2021influential citation
• Helicobacter pylori diagnosis and therapy in the era of antimicrobial stewardship

  2021cites this paper
• Endoscopic Reflux Esophagitis and Reflux-Related Symptoms after Helicobacter pylori Eradication Therapy: Meta-Analysis

  2020cites this paper
• The high-dose amoxicillin-proton pump inhibitor dual therapy in eradication of Helicobacter pylori infection

  2020cites this paper
• Efficacy of second-line regimens for Helicobacter pylori eradication treatment: a systemic review and network meta-analysis

  2020cites this paper
• Effect of a rabeprazole half-dose twice daily on acid inhibition in patients with different CYP2C19 alleles

  2020cites this paper
• Effect of Antibiotic Susceptibility and CYP3A4/5 and CYP2C19 Genotype on the Outcome of Vonoprazan-Containing Helicobacter pylori Eradication Therapy

  2020cites this paper
• Effects of Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Proton Pump Inhibitors.

  2019cites this paper
• Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori

  2019cites this paper
• Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan

  2019cites this paper
• Second-line rescue treatment of Helicobacter pylori infection: Where are we now?

  2018cites this paper
• Helicobacter pylori management in ASEAN: The Bangkok consensus report

  2018cites this paper
• Severity of gastric mucosal atrophy affects the healing speed of post-endoscopic submucosal dissection ulcers

  2018cites this paper
• Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine

  2018cites this paper
• Rifabutin-based Fourth and Fifth-line Rescue Therapy in Patients with for Helicobacter pylori Eradication Failure.

  2017cites this paper
• Four‐times‐daily Dosing of Rabeprazole with Sitafloxacin, High‐Dose Amoxicillin, or Both for Metronidazole‐Resistant Infection with Helicobacter pylori in Japan

  2017cites this paper
• Effects of selective serotonin reuptake inhibitors on the pharmacokinetics of proton pump inhibitors

  2017cites this paper
• Update on the first-line treatment for Helicobacter pylori infection - a continuing challenge from an old enemy

  2017cites this paper
• Optimized high-dose amoxicillin–proton-pump inhibitor dual therapies fail to achieve high cure rates in China

  2017cites this paper
• Meta Analysis Ef fi cacy and safety of high-dose dual therapy for Helicobacter pylori rescue therapy : A systematic review and meta-analysis

  2017cites this paper
• Gastroenteroloji Alaninda Farmakogenetik Bilginin Kullanilmasi The Use of Pharmacogenetic Knowledge in Gastroenterology

  2016cites this paper
• Factors associated with healing of artificial ulcer after endoscopic submucosal dissection with reference to Helicobacter pylori infection, CYP2C19 genotype, and tumor location: Multicenter randomized trial

  2016cites this paper
• Efficacy and safety of high‐dose dual therapy for Helicobacter pylori rescue therapy: A systematic review and meta‐analysis

  2016cites this paper
• [Comparison on Oral versus Intravenous Proton Pump Inhibitors for Prevention of Bleeding after Endoscopic Submucosal Dissection of Gastric Lesions].

  2016cites this paper
• Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis

  2016cites this paper
• Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype

  2016cites this paper
• One-day front-loading with four doses of rabeprazole followed by a standard twice-daily regimen provides sufficient acid inhibition in extensive metabolizers of CYP 2 C 19

  2015influential citation
• Lansoprazole Is Associated with Worsening Asthma Control in Children with the CYP2C19 Poor Metabolizer Phenotype.

  2015cites this paper
• One-day front-loading with four doses of rabeprazole followed by a standard twice-daily regimen provides sufficient acid inhibition in extensive metabolizers of CYP2C19

  2015influential citation
• CYP2C19 Genotype Could be a Predictive Factor for Aggressive Manifestations of Hepatocellular Carcinoma Related with Chronic Hepatitis B Infection in Thailand.

  2015cites this paper
• Effect of bacterial and host factors on Helicobacter pylori eradication therapy

  2015cites this paper
• Potent Gastric Acid Inhibition Over 24 Hours by 4-Times Daily Dosing of Esomeprazole 20 mg

  2015cites this paper
• High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection.

  2015cites this paper
• Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?

  2015influential citation
• High Helicobacter pylori cure rate with sitafloxacin‐based triple therapy

  2015cites this paper
• Efficacy of Tailored Helicobacter pylori Eradication Treatment Based on Clarithromycin Susceptibility and Maintenance of Acid Secretion

  2014cites this paper
• Second and third line treatment options for Helicobacter pylori eradication.

  2014cites this paper
• Treatment of Helicobacter pylori infection: current status and future concepts.

  2014cites this paper
• Prevention of gastric mucosal injury induced by anti‐platelet drugs by famotidine

  2014cites this paper
• Sitafloxacin‐based third‐line rescue regimens for Helicobacter pylori infection in Japan

  2014cites this paper
• Modified sequential Helicobacter pylori eradication therapy using high dose omeprazole and amoxicillin in the initial phase in the extensive metaboliser Turkish patients for CYP2C19 polymorphism is ineffective.

  2014cites this paper
• Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype.

  2014cites this paper
• Implementation of pharmacogenetics in evidence-based medicine: Toward advancing personalized medicine

  2014cites this paper
• Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese

  2014cites this paper
• Evaluation of the relationship between polymorphisms in CYP2C19 and the pharmacokinetics of omeprazole, pantoprazole and rabeprazole.

  2014cites this paper
• Twice‐daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice‐daily omeprazole, rabeprazole or lansoprazole

  2013cites this paper
• A Case of Laparoscopic Surgery in a Young Man with Severe Reflux Esophagitis

  2013cites this paper
• Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Proton Pump Inhibitors

  2013cites this paper
• Functional Polymorphisms in the CYP2C19 Gene Contribute to Digestive System Cancer Risk: Evidence from 11,042 Subjects

  2013cites this paper
• Multilevel D-loop PCR identification of hunting game

  2013cites this paper
• Poor Metabolizers at the Cytochrome P450 2C19 Loci Is at Increased Risk of Developing Cancer in Asian Populations

  2013cites this paper
• Studies Based on CYP2C19 Genotypes

  2013cites this paper
• Antiplatelet Drugs Are a Risk Factor for Esophageal Mucosal Injury

  2013cites this paper
• Dual therapy for third-line Helicobacter pylori eradication and urea breath test prediction.

  2012cites this paper
• Ability of rabeprazole to prevent gastric mucosal damage from clopidogrel and low doses of aspirin depends on CYP2C19 genotype.

  2012cites this paper
• Proton Pump Inhibitor Therapy before and after Endoscopic Submucosal Dissection: A Review

  2012influential citation
• Dose–response relationships of rabeprazole 5, 10, 20, and 40 mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypes

  2012cites this paper
• Efficacy of esomeprazole in treating acid-related diseases in Japanese populations

  2012cites this paper
• Individualized Therapy for Gastroesophageal Reflux Disease

  2012cites this paper
• Evaluation of Six Cases of Idiopathic Gastric Antral Ulcer

  2012cites this paper
• Rabeprazole 10 mg q.d.s. decreases 24‐h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype

  2012cites this paper
• Predicting the efficacy of proton pump inhibitors in patients with non‐erosive reflux disease before therapy using dual‐channel 24‐h esophageal pH monitoring

  2012cites this paper
• Ilaprazole, a new proton pump inhibitor, is primarily metabolized to ilaprazole sulfone by CYP3A4 and 3A5

  2012influential citation
• Individualized therapy for gastroesophageal reflux disease: potential impact of pharmacogenetic testing based on CYP2C19.

  2012cites this paper
• A comparison of the acid‐inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism

  2012cites this paper
• High‐dose rabeprazole–amoxicillin dual therapy and rabeprazole triple therapy with amoxicillin and levofloxacin for 2 weeks as first and second line rescue therapies for Helicobacter pylori treatment failures

  2012cites this paper
• Original article Ilaprazole for the treatment of duodenal ulcer: a randomized, double-blind and controlled phase III trial

  2012cites this paper
• Ilaprazole for the treatment of duodenal ulcer: a randomized, double-blind and controlled phase III trial

  2012cites this paper
• Translating pharmacogenetics to primary care

  2011cites this paper
• Characteristics of non-erosive gastroesophageal reflux disease refractory to proton pump inhibitor therapy.

  2011cites this paper
• [Helicobacter pylori eradication therapy in Korea].

  2011cites this paper
• ２． 消化器内科の立場から（PPI併用賛成派)

  2011cites this paper
• Association of functionally important polymorphisms in cytochrome P450s with squamous cell carcinoma of head and neck.

  2010cites this paper
• Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes.

  2010cites this paper
• The dual therapy with 4 times daily dosing of rabeprazole and amoxicillin as the 3rd rescue regimen for eradication of H. pylori.

  2010cites this paper
• Clinical effects of proton pump inhibitors: Focus on pharmacogenetics, kinetics and dynamics

  2010cites this paper
• Interaction of drug metabolizing cytochrome P450 2D6 poor metabolizers with cytochrome P450 2C9 and 2C19 genotypes modify the susceptibility to head and neck cancer and treatment response.

  2010cites this paper
• Esophageal Mucosal Injury With Low‐Dose Aspirin and Its Prevention by Rabeprazole

  2010cites this paper
• Effect of CYP2C19 genotypes on the pharmacokinetic/pharmacodynamic relationship of rabeprazole after a single oral dose in healthy Chinese volunteers

  2010cites this paper
• Optimal dose of intravenous pantoprazole in patients with peptic ulcer bleeding requiring endoscopic hemostasis in Korea

  2009cites this paper
• Influence of inflammatory cytokine polymorphisms on eradication rates of Helicobacter pylori

  2009cites this paper
• Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy

  2009influential citation
• Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori.

  2009cites this paper
• Proton Pump Inhibitors – Their Pharmacological Impact on the Clinical Management of Acid-Related Disorders

  2009influential citation
• CYP2C19 genotype is associated with symptomatic recurrence of GERD during maintenance therapy with low-dose lansoprazole

  2009cites this paper